Structures of Mycobacterium tuberculosis RNA polymerase reveal taxon-specific properties and binding sites of known and new antituberculosis agents.
molecular volume as Eco σR1.1, σR1.1 in Mtb RPo and RPitc occupies essentially the entire space between β'MtbSI and dsDNA, potentially making a continuous chain of β'MtbSI-σR1. 1- dsDNA interactions that close the active center and help trap and secure dsDNA in the active center ( Figs. 1B, S8B ). Consistent with this inference, deletion of Mtb σR1.1 strongly reduces the stability of Mtb RPo (5-fold defect), and deletion of both Mtb σR1.1 and β'MtbSI very strongly reduces the stability of RPo (40-fold defect; Fig. 1C ).
We determined a crystal structure of Mtb RPo in complex with Rif using analogous procedures ( Fig. 2A-C ; Table S2 ). The structure shows RNAP-Rif interactions similar to those in previously reported structures of Tth RNAP and Eco RNAP in complex with rifamycins (11) (12) (13) , but, in this case, with a Rif binding-site sequence from a bacterial species for which Rif is a clinically relevant antibacterial drug ( Fig. 2A-C) . The structure shows direct H-bonded contacts between Rif and two of the three residues most frequently substituted in Rif-resistant Mtb clinical isolates (β H526 and S531) and direct van der Waals interactions between Rif and the third (β D516) (2-3; Fig. 2B -C).
A series of crystal structures of Mtb RPitc in complex with Rif, obtained by crystallizing a pre-formed Mtb RNAP-Rif complex with nucleic-acid scaffolds containing RNA oligomers corresponding to 2, 3, and 4 nt RNA products (Table S3 ). The results graphically demonstrate that Rif inhibits transcription through a "steric occlusion" mechanism that prevents extension of 2-3 nt RNA products to yield longer RNA products--a mechanism that previously had been proposed (11, (14) (15) , but that had not been directly demonstrated and had been controversial (12, 15) (Fig. 2D-E ; Tables S1-S2). Thus, whereas, in the absence of Rif, 2, 3, and 4 nt RNA products fully base pair to the DNA template strand, (Fig. 2D ), in the presence of Rif, the 5' nucleotide of a 3 nt RNA is unpaired, unstacked, and rotated by ~40°, due to steric clash with Rif ( Fig. 2E , second and fourth panels), and a 4 nt RNA is unable to interact stably with the complex (i.e., shows no density; Fig. 2E , third panel). All the Mtb RPo-Rif and RPitc-Rif structures show clear, unambiguous electron density for the RNAP active-center catalytic Mg 2+ , inconsistent with the alternative, "allosteric" mechanism for Rif function proposed in 12 (Fig. 2D-E) . Table S3 ). Synthesis of a D-AAP1 analog containing a carbon-to-selenium substitution, D-IX336, followed by crystal soaking, X-ray diffraction analysis, and seleniumanomalous-dispersion analysis confirms the identified binding site, orientations, and interactions (Figs. 3A-C, S10; Table S3 ). The structures reveal that AAPs bind to Mtb RNAP at a binding site centered on the N-terminus of the RNAP bridge helix (an α-helix that bridges the RNAP active-center cleft and forms one wall of the RNAP active center; Fig. 3B 3E ). The structures enable rational, structure-based optimization of AAPs to improve potencies and properties. In particular, the structures show that the methyl group of ring "C" of an AAP projects into an unoccupied area (Figs. 3B-D), allowing substitution of this position with diverse chemical functionality. Lead-optimization efforts (to be described elsewhere) confirm the utility of the structures for structure-based lead optimization, and, in particular, confirm the ability to improve potency and properties by substitution of the methyl group of ring "C."
The structures in Fig. 3 show that the binding site on RNAP for AAPs differs from, and does not overlap, the binding site on RNAP for Rif (Figs. 2A, 3B-C). The binding site on RNAP for AAPs is similar in location to the binding site for CBRs, a class of compounds that inhibit Gram-negative bacterial RNAP but do not inhibit Mycobacterial RNAP; 16-18; Fig. S11 ). Thus, both AAPs (in Mtb RNAP) and CBRs (in Gram-negative RNAP) interact with the RNAP bridgehelix N-terminus (Figs. 3B-D; S11). We infer that AAPs are Mycobacteria-selective inhibitors that function through the bridge-helix N-terminus target, and CBRs are Gram-negative-selective inhibitors that function through the bridge-helix N-terminus. Comparison of structures of Mtb RNAP-AAP complexes and Eco RNAP-CBR complexes reveals the basis for the difference in selectivity: i.e., because of sequence differences, Mtb RNAP has a three-pocket site complementary to an AAP, with three rings, but Eco RNAP has a two-pocket site complementary to a CBR, with two rings (Figs. S11-S12). The crucial sequence differences apparently include β residue 642 and β' residues 757 and 771, which line or approach the pocket that is present, and accommodates AAP ring "A," in Mtb RNAP, but is absent in Eco RNAP (residues numbered as in Eco RNAP; Figs S11-S12). Based on the similarity in binding sites of AAPs and CBRs, AAPs most likely inhibit RNAP through a mechanism similar to that of CBRs:
i.e., interference with bridge-helix conformational dynamics required for nucleotide addition (17) (18) .
A structure of Mtb RPo in complex with both D-AAP1 and Rif further confirms unequivocally that the AAP binding site differs from, and does not overlap, the Rif binding site and shows that an AAP and Rif can bind simultaneously to RNAP ( Fig. 4A ; Table S3 ).
The absence of overlap between the AAP and Rif binding sites ( 
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Nα-benzoyl-N-(2-methylphenyl)-D-phenylalaninamide (D-AAP1).
D-IX336
To a suspension of N-Fmoc-D-phenylalanine (2 g, 5.16 mmol; Chem-Impex, Inc.) in 20 ml dichloromethane was added oxalyl chloride (0.66 ml, 7.74 mmol; Sigma-Aldrich, Inc.) and 200 μl dimethylformamide. After stirring for 30 min, the reaction mixture was evaporated to dryness (to remove any trace of unreacted oxalyl chloride) and re-dissolved in 30 ml dichloromethane. O-toluidine (0.554 ml, 5.16 mm; Sigma-Aldrich, Inc.) was added drop-wise followed by addition of DIPEA (1.08 ml, 6.19 mm). The reaction was stirred for 2 h, and 0.5 M HCl was used to acidify the mixture, which was then extracted with 3 x 30 ml dichloromethane. The organic extract was filtered, washed with brine, dried with anhydrous sodium sulfate, and evaporated to a solid, providing (9H-fluoren-9-yl) methyl (R)-(1-oxo-3-phenyl-1-(o-tolylamino) propan-2-yl) carbamate, which was used without purification in the next step. . Single colonies of the resulting transformants were used to inoculate 50 ml LB broth containing 50 µg/ml kanamycin, and cultures were incubated 16 h at 37°C with shaking. Aliquots (10 ml) were used to inoculate 1 L LB broth containing 50 µg/ml kanamycin, cultures were incubated at 37°C with shaking until OD 600 = 0.8, cultures were induced by addition of IPTG to 1 mM, and cultures were incubated overnight at 16°C. Cells were harvested by centrifugation (4,000 x g; 15 min at 4°C), resuspended in 20 ml buffer A (10 mM Tris-HCl, pH 7.9, 0.2 M NaCl, 5% glycerol), and lysed using an EmulsiFlex-C5 cell disrupter (Avestin, Inc.). The lysate was centrifuged (20,000 x g; 30 min at 4°C), and the supernatant was loaded onto a 5 ml column of Ni-NTA-agarose (Qiagen, Inc.) equilibrated in buffer A. The column was washed with 50 ml buffer A containing 40 mM imidazole and eluted with 25 ml buffer A containing 0.25 M imidazole. The sample was further purified using by gel filtration on a Superdex G500 column (GE Healthcare, Inc) in 20 mM Tris-HCl, pH 8.0, 75 mM NaCl, 5 mM MgCl 2 , and was concentrated to ~10 mg/L in the same buffer using 10 kDa MWCO Amicon Ultra-15 centrifugal ultrafilters (Millipore, Inc.) and stored at -80°C. Yields were ~20 mg/L, and purities were >95%.
Selenomethionine-substituted β'MtbSI protein was produced using plasmid pET28a-Mtb-β'MtbS and the procedures of 20 and was purified as for native β'MtbSI.
M. tuberculosis RNAP core enzyme. Mtb RNAP core enzyme and RNAP core enzyme derivatives were prepared from cultures of E. coli strain BL21 (DE3) (Invitrogen, Inc.) co-transformed with plasmids pACYC-σ A , pCOLADuet-rpoBC, and pCDF-rpoZ (21) , or derivatives thereof constructed using site-directed mutagenesis (QuickChange Kit; Agilent Biotechnology, Inc.), using procedures as in 21.
M. tuberculosis RNAP σ A holoenzyme.
Mtb RNAP σ A holoenzyme and RNAP σ A holoenzyme derivatives were prepared from cultures of E. coli strain BL21 (DE3) (Invitrogen, Inc.) co-transformed with plasmids pACYC-rpoA-σ A , pETDuet-rpoBC and pCDF-rpoZ (21) , or derivatives thereof constructed using site-directed mutagenesis (QuikChange Kit; Agilent Biotechnology, Inc.), using procedures as in 21.
Oligonucleotides. Oligodeoxyribonucleotides (IDT, Inc.) and oligoribonucleotides (GpA, GpGpA, and UpCpGpA; Trilink, Inc.) were dissolved in nuclease-free water (Ambion, Inc.) to 3 mM and stored at -80°C.
Nucleic-acid scaffolds. Nucleic-acid scaffolds RPo, RPitc3, and RPitc4 (sequences in Fig. S1C ) were prepared as follows: Nontemplate-strand oligodeoxyribonucleotide (0.5 mM), template-strand oligodeoxyribonucleotide (0.55 mM), and, where indicated, 3 nt or 4 nt oligoribonucleotide (1 mM) in 40 µl 5 mM Tris-HCl, pH 7.7, 0.2 M NaCl, and 10 mM MgCl 2 were heated 5 min at 95°C, cooled to 25°C in 2°C steps with 1 min per step using a thermal cycler (Applied Biosystems, Inc.), and stored at -80°C. 
RNAP-DNA interaction assays. Stabilities of
where I VV and I VH are fluorescence intensities with the excitation polarizer at the vertical position and the emission polarizer at, respectively, the vertical position and the horizontal position.
Equilibrium dissociation constants, K D , were extracted by non-linear regression using:
where P is fluorescence polarization at RNAP concentration R, P f is fluorescence polarization in the absence of RNAP, and P b is the fluorescence polarization in the presence of a saturating RNAP concentration. Radiochemical assays with human RNAP I/II/III were performed as in 25.
RNAP-inhibitory activities. Fluorescence
Half-maximal inhibitory concentrations (IC50s) were calculated by non-linear regression in SigmaPlot (SPSS, Chicago, IL). Resistance and cross-resistance levels were determined in broth microdilution assays (see above, "Growth-inhibitory activities"), using final concentrations of 0.0015-50 μg/ml D-AAP or Rif.
Growth-inhibitory activities. Minimal inhibitory concentrations (MICs) for
Checkerboard interaction assays.
To assess antibacterial activities of combinations of D-AAP1 and Rif, broth-microdilution assays with M. smegmatis ATCC 19420 (see above, "Growth inhibitory activities") were performed in a checkerboard format (29) (30) (31) 
